News|Articles|November 18, 2026

Experts Discuss Personalized Treatment Strategies for Psoriasis

Listen
0:00 / 0:00

Key Takeaways

  • Treatment escalation should incorporate functional impairment, treatment burden, and occupational feasibility, not BSA alone, particularly when topical adherence is intrinsically impractical.
  • Cardiometabolic comorbidities warrant viewing psoriasis as systemic inflammation, prompting earlier systemic therapy consideration and highlighting the need for cardiovascular outcomes data.
SHOW MORE

Dermatology experts discuss systemic therapy selection, comorbidities, adherence, and access barriers through 2 plaque psoriasis patient cases.

Managing plaque psoriasis requires more than evaluating skin clearance. Comorbidities, occupational demands, treatment adherence, and patient preferences can significantly influence therapeutic decisions, particularly as the number of available systemic therapies continues to expand.

During a Dermatology Times Case-Based Roundtable in New York City, Christopher Bunick, MD, PhD, dermatologist at Yale School of Medicine and editor-in-chief of Dermatology Times, led clinicians through 3 patient cases highlighting the challenges of individualizing psoriasis management.

The discussion explored when to escalate beyond topical therapies, how to select biologics for patients with complex medical histories, and the importance of matching treatment regimens to patients' lifestyles and abilities to maintain long-term therapy.

Case 1: Addressing Moderate Psoriasis and Cardiovascular Risk

The first case involved a 39-year-old roofing contractor with an 8-year history of plaque psoriasis affecting approximately 15% of his body surface area (BSA), primarily on his trunk and arms.

The patient reported worsening symptoms with sweating, sun exposure, and friction from his work equipment. His medical history included obesity and hypertension, along with a family history of premature coronary artery disease. Although he had previously used topical corticosteroids, adherence was inconsistent, and he had not received systemic or biologic therapy.

Clinicians identified several factors supporting treatment escalation, including the extent of skin involvement, inadequate disease control with topical therapy, and the practical challenges of applying medication while working outdoors.

Bunick guided the discussion toward the broader implications of psoriasis as a systemic inflammatory disease, particularly in patients with existing cardiovascular risk factors.

Participants considered how the patient's occupational exposure, treatment preferences, and comorbidities could influence the selection of systemic therapy. The conversation also addressed the limitations of relying on topical corticosteroids when disease severity and treatment burden warrant a different approach.

The case reinforced the importance of assessing more than BSA when determining treatment eligibility. Functional impairment, treatment feasibility, and the potential consequences of prolonged uncontrolled disease were central considerations.

Case 2: Simplifying Treatment for an Older Patient

The second case centered on a 72-year-old retired school administrator with plaque psoriasis affecting approximately 12% BSA, primarily on her elbows, knees, and lower back.

Unlike the first patient, she experienced substantial pruritus that interfered with sleep and daily activities. Plaques on her knees were particularly bothersome and contributed to difficulty walking.

Her medical history included hand osteoarthritis and medically controlled type 2 diabetes. Although she had previously received topical corticosteroids and roflumilast, arthritis made topical application difficult. She also struggled to maintain a consistent oral medication routine.

Bunick asked participants to consider how age, functional limitations, and living independently might affect treatment selection.

The discussion highlighted the potential advantages of less frequent dosing and health care professional-administered treatment for patients who have difficulty applying topical medications or remembering oral therapies.

Participants discussed biologics with extended maintenance dosing intervals, including tildrakizumab, as a possible strategy for reducing treatment burden. One clinician suggested scheduling office visits every 12 weeks for medication administration, allowing the care team to support adherence while maintaining regular contact with the patient.

The conversation also examined treatment persistence among older adults and the potential role of office-based administration in helping patients remain on therapy.

Ultimately, the case demonstrated that treatment convenience and accessibility can be as important as efficacy when developing a sustainable psoriasis management plan.

Case 3: Managing Severe Psoriasis After Inadequate Biologic Response

The final case involved a 34-year-old emergency department nurse with plaque psoriasis affecting approximately 50% BSA, including her scalp and fingernails.

Diagnosed at age 28, the patient had experienced progressive disease despite intermittent topical corticosteroid use and 6 months of treatment with secukinumab, an interleukin (IL)-17A inhibitor.

Her rotating 12-hour day and overnight shifts complicated treatment adherence, while irregular sleep and the physical demands of her job appeared to coincide with disease flares. Her medical history also included anxiety and migraines.

Bunick invited participants to consider both the clinical implications of an inadequate response to secukinumab and the psychosocial challenges associated with managing extensive psoriasis.

Clinicians discussed whether to switch to another therapy within the IL-17 inhibitor class or transition to a different mechanism of action, including IL-23 inhibition.

The patient's scalp and nail involvement introduced additional considerations. Participants reviewed clinical efficacy data related to these difficult-to-treat areas and discussed how the extent and location of disease might influence their therapeutic choices.

Treatment administration was another major theme. Because the patient worked at the same hospital as her dermatology practice, clinicians suggested that office-administered injections might help accommodate her unpredictable schedule and reduce the burden of self-administration.

The case emphasized the importance of reassessing both treatment efficacy and feasibility when patients experience inadequate disease control.

Balancing Efficacy, Adherence, and Long-Term Outcomes

Across the 3 cases, participants repeatedly returned to the importance of shared decision-making and individualized treatment selection.

Although biologic efficacy remains a central consideration, clinicians emphasized that treatment success also depends on whether patients can realistically maintain a prescribed regimen.

The discussion addressed how injection frequency, administration setting, insurance requirements, occupational demands, and functional limitations can influence treatment persistence.

Bunick also encouraged participants to consider the broader health implications of psoriasis, including the relationship between chronic inflammation and cardiovascular disease.

During the closing discussion, he highlighted the need for additional cardiovascular outcomes data to better understand whether interventions for psoriasis can alter patients' long-term cardiovascular risk.

The roundtable reinforced that optimal psoriasis management requires a comprehensive assessment of disease severity, comorbidities, treatment history, and individual circumstances. Rather than applying a uniform therapeutic approach, clinicians emphasized developing treatment plans that patients can sustain while working toward meaningful disease control.


Related to this article